Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
midazolam + propofol + sufentanil + remifentanil + rocuronium
- Development stage
- Unknown
- Lead developer
- Beijing Friendship Hospital
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
midazolam + propofol + sufentanil + remifentanil + rocuronium is a multi-drug anesthetic regimen used for the induction and maintenance of general anesthesia. This specific combination serves as the traditional opioid-based control arm in clinical research conducted by Beijing Friendship Hospital. The regimen includes midazolam for sedation and amnesia, propofol as a primary hypnotic agent, sufentanil and remifentanil as potent mu-opioid receptor agonists for analgesia, and rocuronium as a neuromuscular blocker to facilitate surgery. It is typically administered intravenously and is being studied in elderly populations to compare its recovery profile against opioid-free alternatives.
- Other names
- opioid group-Beijing Friendship Hospital-general anesthesiaOpioid groupOpioid-based anesthesia
02
Targets
Muscle-type nicotinic acetylcholine receptorGABRR (GABA-A receptor subunit rho)MOR (Mu opioid receptor)BZD site (GABA-A receptor benzodiazepine site)NMDAR (Glutamate receptor ionotropic, NMDA)
Beyond the preview
Go deeper on midazolam + propofol + sufentanil + remifentanil + rocuronium.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on midazolam + propofol + sufentanil + remifentanil + rocuronium.